Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/171764
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChia, Wan Nien_US
dc.contributor.authorTan, Chee Wahen_US
dc.contributor.authorTan, Aaron Wai Kiten_US
dc.contributor.authorYoung, Barnabyen_US
dc.contributor.authorStarr, Tyler N.en_US
dc.contributor.authorLopez, Esteren_US
dc.contributor.authorFibriansah, Gunturen_US
dc.contributor.authorBarr, Jenniferen_US
dc.contributor.authorCheng, Samuelen_US
dc.contributor.authorYeoh, Aileen Ying-Yanen_US
dc.contributor.authorYap, Wee Cheeen_US
dc.contributor.authorLim, Beng Leeen_US
dc.contributor.authorNg, Thiam-Sengen_US
dc.contributor.authorSia, Wan Rongen_US
dc.contributor.authorZhu, Fengen_US
dc.contributor.authorChen, Shiweien_US
dc.contributor.authorZhang, Jinyanen_US
dc.contributor.authorKwek, Madeline Sheng Sien_US
dc.contributor.authorGreaney, Allison J.en_US
dc.contributor.authorChen, Marken_US
dc.contributor.authorAu, Gough G.en_US
dc.contributor.authorParadkar, Prasad N.en_US
dc.contributor.authorPeiris, Maliken_US
dc.contributor.authorChung, Amy W.en_US
dc.contributor.authorBloom, Jesse D.en_US
dc.contributor.authorLye, Daviden_US
dc.contributor.authorLok, Sheemeien_US
dc.contributor.authorWang, Lin-Faen_US
dc.date.accessioned2023-11-07T05:57:15Z-
dc.date.available2023-11-07T05:57:15Z-
dc.date.issued2023-
dc.identifier.citationChia, W. N., Tan, C. W., Tan, A. W. K., Young, B., Starr, T. N., Lopez, E., Fibriansah, G., Barr, J., Cheng, S., Yeoh, A. Y., Yap, W. C., Lim, B. L., Ng, T., Sia, W. R., Zhu, F., Chen, S., Zhang, J., Kwek, M. S. S., Greaney, A. J., ...Wang, L. (2023). Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor. Science Advances, 9(30), eade3470-. https://dx.doi.org/10.1126/sciadv.ade3470en_US
dc.identifier.issn2375-2548en_US
dc.identifier.urihttps://hdl.handle.net/10356/171764-
dc.description.abstractThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern such as Omicron hampered efforts in controlling the ongoing coronavirus disease 2019 pandemic due to their ability to escape neutralizing antibodies induced by vaccination or prior infection, highlighting the need to develop broad-spectrum vaccines and therapeutics. Most human monoclonal antibodies (mAbs) reported to date have not demonstrated true pan-sarbecovirus neutralizing breadth especially against animal sarbecoviruses. Here, we report the isolation and characterization of highly potent mAbs targeting the receptor binding domain (RBD) of huACE2-dependent sarbecovirus from a SARS-CoV survivor vaccinated with BNT162b2. Among the six mAbs identified, one (E7) showed better huACE2-dependent sarbecovirus neutralizing potency and breadth than any other mAbs reported to date. Mutagenesis and cryo-electron microscopy studies indicate that these mAbs have a unique RBD contact footprint and that E7 binds to a quaternary structure-dependent epitope.en_US
dc.language.isoenen_US
dc.relation.ispartofScience Advancesen_US
dc.rights© 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).en_US
dc.subjectScience::Medicineen_US
dc.titlePotent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivoren_US
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.contributor.organizationNational Center of Infectious Diseases, Singaporeen_US
dc.contributor.organizationTan Tock Seng Hospitalen_US
dc.identifier.doi10.1126/sciadv.ade3470-
dc.description.versionPublished versionen_US
dc.identifier.pmid37494438-
dc.identifier.scopus2-s2.0-85165884069-
dc.identifier.issue30en_US
dc.identifier.volume9en_US
dc.identifier.spageeade3470en_US
dc.subject.keywordsCryo-Electron Microscopyen_US
dc.subject.keywordsHuman Monoclonal Antibodiesen_US
dc.description.acknowledgementThe work conducted at Duke-NUS was supported in part by Singapore National Research Foundation grant NRF2016NRF-NSFC002-013 (L.-F.W.), National Medical Research Council Singapore grant STPRG-FY19-001 (L.-F.W.), National Medical Research Council Singapore grant COVID19RF-003 (L.-F.W.), National Medical Research Council Singapore grant COVID19RF-060 (L.-F.W.), National Medical Research Council Singapore grant MOH000535/MOH-OFYIRG19nov-0002 (C.W.T.), and National Medical Research Council Singapore grant OFLCG19May-0034 (L.-F.W.). The work conducted at University of Melbourne was supported in part by National Health and Medical Research Center Investigator grant GNT 2008092 (A.W.C.). The work conducted at Fred Hutchinson Cancer Research Centre was supported in part by the Damon Runyon Cancer Research Foundation (T.N.S.) and NIAIH/NIH grant K99AI166250 (T.N.S.).en_US
item.grantfulltextopen-
item.fulltextWith Fulltext-
Appears in Collections:LKCMedicine Journal Articles
Files in This Item:
File Description SizeFormat 
sciadv.ade3470.pdf1.79 MBAdobe PDFThumbnail
View/Open

SCOPUSTM   
Citations 50

3
Updated on Jul 21, 2024

Page view(s)

79
Updated on Jul 24, 2024

Download(s)

24
Updated on Jul 24, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.